Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.67 |
| ▸ | TNF | P01375 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.58 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisofylline SCHEMBL39131 | 1.00 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL680306 | 1.00 | ADORA2B (0.67) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6777369 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6779520 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6774460 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6780935 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL10508600 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Lisofylline SCHEMBL10517408 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8686678 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL6778207 | 0.99 | ADORA2B (0.66) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9918987-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| CN-106456647-A | Methods of treating hyperglycemia | 康塞特医药品有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9492457-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150376665-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | CONCERT PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9074233-B2 | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation | CONCERT PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
| US-6780865-B1 | SUBSTITUTED CHIRAL XANTHINE COMPOUND, STABILITY IN ADVERSE CHEMICAL AND DYNAMIC BIOLOGIC ENVIRONMENTS | CELL THERAPEUTICS, INC. | 2004-08-24 | — | — | US | disclosed |
| US-6469017-B1 | IN INFLAMMATORY DISORDERS; INHIBITION OF IL-12 SIGNALING DECREASES THE PRODUCTION OF IFN-GAMMA, THUS MITIGATING THE INFLAMMATORY RESPONSE IN DISEASE | CELL THERAPEUTICS, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6075029-A | Xanthine modulators of metabolism of cellular P-450 | CELL THERAPEUTICS, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5710272-A | INCREASING CEREBRAL BLOOD FLOW | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-20 | — | — | US | disclosed |
| EP-0435152-B1 | Process for the enantioselective preparation of (omega-1)-hydroxyalkylxanthines | HOECHST AG (DE) | 1996-11-13 | — | — | EP | disclosed |
| US-5472873-A | Rhodotorula rubra useful in a process for the preparation of (ω-1)-hydroxyalkylxanthines | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-05 | — | — | US | disclosed |
| US-5310666-A | Vascular disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-10 | — | — | US | disclosed |
| EP-0435152-A2 | Process for the enantioselective preparation of (omega-1)-hydroxyalkylxanthines | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | ADORA2B 116/4885TNF 45/4885USP2 649/4885 |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20150376665-A1 | PROCESS FOR PREPARING AN ENANTIOMERICALLY ENRICHED, DEUTERATED SECONDARY ALCOHOL FROM A CORRESPONDING KETONE WITHOUT REDUCING DEUTERIUM INCORPORATION | ADH1A, ADH1C, ADH5 | ADORA2B 3309/4885TNF 4258/4885USP2 2600/4885 |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | IL1B, IAPP, CXCL12 | ADORA2B 1060/4885TNF 39/4885USP2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.